Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Dimerix Limited secures A$34 million non-dilutive loan facility aimed at funding key clinical milestones. This funding enhances financial flexibility for ongoing clinical development programs.
Dimerix Limited has successfully secured non-dilutive loan facility agreements with lenders, allowing access to A$34 million. This funding will support the company's clinical programs without diluting shareholder value. The financial flexibility is crucial for completing critical trials related to kidney disease treatments. Dimerix is dedicated to improving outcomes for patients suffering from serious kidney conditions.
Company Information
Company
Dimerix Limited
Location
Melbourne, Victoria, Australia
About
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Don't miss Dimerix Limited's next move
Get an email the moment Dimerix Limited raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contactsNina, CEO & Managing Director
Predictive Intelligence
Strategic
ML-powered predictions for Dimerix Limited's next move
MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma